Education Library

Resources for Health Care Professionals

Filter Results

Condition

Audience

Topic

Type

DanGer Shock Randomized Control Trial FAQs

The significance of the DanGer Shock trial lies in its milestone findings for cardiology, potentially reshaping patient care by establishing routine Impella use as a life-saving intervention for STEMI patients with shock.

Ripped From the Headlines of ACC: DanGer Shock RCT Results

A panel of interventional cardiologists discuss the DanGer Shock RCT results and the implications for AMICS patient management.

European Best Practice A Step Forward to Optimize Impella-Protected Percutaneous Coronary Intervention To Improve Outcomes After High-Risk Coronary Interventions

This overview article provides a framework for this series of articles. It addresses European recommendations and best practices for patient management and mechanical circulatory support (MCS) during high risk intervention, highlighting the following topics...

Babar Basir: Importance of Multidisciplinary Care for Cardiogenic Shock

Babar Basir, DO, describes the importance of multidisciplinary care for patients with cardiogenic shock.

Successful Mechanical Circulatory Support (MCS) in Cardiogenic Shock Patients - A Glimpse into the Future

This article examines current evidence for the use of mechanical circulatory support (MCS) in cardiogenic shock and discusses how the scientific community can advance research in this area.

Babar Basir: Best Practices in Revascularization in Cardiogenic Shock

Babar Basir, D.O., discusses revascularization best practices in patients with cardiogenic shock.

Babar Basir: Increased Use of Best Practices Since NCSI

Babar Basir, DO, highlights the increased use of acute mechanical circulatory support best practices since the National Cardiogenic Shock Initiative (NCSI) study.

Impella 5.5® with SmartAssist® Best Practices: OR and ICU Checklists

Bessie Sycip presents OR and ICU best practice checklists for Impella 5.5® with SmartAssist®.

DanGer Shock Results at ACC 2024 from Jacob Møller, M.D.

Jacob Møller, M.D., the principal investigator of the DanGer Shock trial, discusses the study results he presented at ACC 2024.

Babar Basir: Importance of Door-To-Support in Cardiogenic Shock

Babar Basir, DO, discusses the evolving understanding of the importance of unloading with Impella® in patients with cardiogenic shock. 

Babar Basir: Predictors of Outcomes From NCSI

Babar Basir, DO, highlights trends and opportunities to improve outcomes using data from the National Cardiogenic Shock Initiative (NCSI) study.

Successful Mechanical Circulatory Support (MCS) in Cardiogenic Shock Patients

Experts throughout Europe have contributed to this European Heart Journal supplement with articles discussing best practices for successfully managing mechanical circulatory support (MCS) in patients with cardiogenic shock.

A Decade of Progress in Cardiogenic Shock Treatment: DanGer Shock RCT, a Milestone in Cardiogenic Shock Trials

Babar Basir, D.O., discusses the impact of the DanGer Shock RCT in clinical practice and looks into the future of AMI cardiogenic shock treatment and management.

Recognizing Patients as Candidates for Mechanical Circulatory Support Along the Spectrum of Cardiogenic Shock

This paper discusses the latest guidance for identifying patients with cardiogenic shock (CS) who are candidates for mechanical circulatory support (MCS).

Optimal Bail-Out and Complication Management Strategies in Protected High-Risk Percutaneous Coronary Intervention With the Impella Heart Pump

In this article the authors describe techniques for Impella heart pump removal with or without pre-closure and discuss how to prevent and manage complications associated with large-bore femoral access.

NPS-1674

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].